Previous research has suggested that GLP-1 receptor agonists may offer benefits in inflammatory bowel disease.In a retrospective cohort study of patients with ulcerative colitis, use of liraglutide or semaglutide was associated with higher remission rates compared with no use at 12 weeks.Weight loss was not independently associated with remission.
The use of GLP-1 receptor agonists was linked to improved remission rates in patients with ulcerative colitis, a retrospective cohort study suggested.
Among 300 patients with ulcerative colitis, use of liraglutide (Victoza, Saxenda) or semaglutide (Ozempic, Wegovy) for metabolic indications was associated with higher remission rates compared with no use at 4 weeks (34.7% vs 15.3%, P=0.001), 8 weeks (54.7% vs 18%, P<0.001), and 12 weeks (66.7% vs 25.3%, P<0.001), reported Budoor Alqinai, MBChB, MSc, of West Virginia University in Morgantown, and colleagues.
After adjusting for age, sex, baseline partial Mayo score, obesity, diabetes status, and category of concomitant biologic therapy, the use of GLP-1 drugs was strongly and independently associated with symptomatic remission (adjusted OR 5.90, 95% CI 3.52-9.86, P<0.001), they noted in Inflammatory Bowel Diseases.
